Does the presence of interstitial lung disease (excluding IPF) affect your decision to offer conventional fractionated RT for Stage III NSCLC?

Tough question. I think a key step would be how certain the diagnosis of ILD is. I.e., was this a comment incidentally on a CT scan from radiology, or does the patient have active ILD management by a pulmonologist? Certainly, UIP patients appear to have higher rates of severe toxicity following RT. ...